Wharton Asset Management Company Limited
VC Fund
London, United Kingdom
Wharton Asset Management Company Limited is a VC fund in London focused on Health Care and Biotechnology. Wharton Asset Management is an investment management company.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 60%
Last updated:
For AI agents: llms.txt
Industries Wharton Asset Management Company Limited invests in
Health CareBiotechnologyMedicalSecuritySoftware
Stages Wharton Asset Management Company Limited invests in
Series AVenture - Series UnknownSeedFunding Round
Countries Wharton Asset Management Company Limited invests in
United Kingdom
Round sizes
Seed $3.9M–$4.6MSeries A $1.9M–$6.5MVenture - Series Unknown $6.7M–$12M
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $3.9M–$4.6M
- Series A
- $1.9M–$6.5M
- Venture - Series Unknown
- $6.7M–$12M
Investment Focus
Industry
- Health Care 3 (30%)
- Biotechnology 2 (20%)
- Medical 1 (10%)
- Security 1 (10%)
- Software 1 (10%)
Stage
- Series A 3 (30%)
- Venture - Series Unknown 2 (20%)
- Seed 1 (10%)
- Funding Round 1 (10%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Wharton Asset Management Company Limited
Managing Director
|
Managing Director | Total investments: 3 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Neurovalens delivers innovative solutions in the field of neuroscience, bioscience and neurophysiology.Neurovalens has received support from Invest NI under the European Union’s Investment for Growth and Jobs Programme. The project, recorded on the ERDF beneficiaries’ website, will be implemented over the next one year, undertaking research anddevelopment activities aimed at improving the competitiveness of the business. | $6.7M / Venture - Series Unknown / Aug 19, 2025 | ||
| B-Secur are on a mission to revolutionise the way people experience technology in the connected world using their unique heartbeat. We’ve invested over 15 years of deep, scientific research in ECG to become a world leader in the development and integration of ECG technology, partnering with some of the world's leading technology companies.We’ve harnessed the power of ECG to create HeartKey®, offering advanced physiological monitoring with intrinsic data protection.We have developed a suite of powerful ECG algorithms and analytics for user identification, wellness, and health, ready for integration into leading devices and systems. B-Secur also have a combined 50+ years of in-house hardware and material science, which our partners can use to significantly reduce development costs on hardware and ECG electrode design. B-Secur and HeartKey® bring you our world class expertise in ECG combined with powerful, flexible integration and configuration possibilities to create your optimal product, with a competitive edge. | $11.9M / Venture - Series Unknown / Nov 04, 2021 | ||
| B-Secur are on a mission to revolutionise the way people experience technology in the connected world using their unique heartbeat. We’ve invested over 15 years of deep, scientific research in ECG to become a world leader in the development and integration of ECG technology, partnering with some of the world's leading technology companies.We’ve harnessed the power of ECG to create HeartKey®, offering advanced physiological monitoring with intrinsic data protection.We have developed a suite of powerful ECG algorithms and analytics for user identification, wellness, and health, ready for integration into leading devices and systems. B-Secur also have a combined 50+ years of in-house hardware and material science, which our partners can use to significantly reduce development costs on hardware and ECG electrode design. B-Secur and HeartKey® bring you our world class expertise in ECG combined with powerful, flexible integration and configuration possibilities to create your optimal product, with a competitive edge. | $1.9M / Series A / Sep 15, 2020 | ||
| Neurovalens delivers innovative solutions in the field of neuroscience, bioscience and neurophysiology.Neurovalens has received support from Invest NI under the European Union’s Investment for Growth and Jobs Programme. The project, recorded on the ERDF beneficiaries’ website, will be implemented over the next one year, undertaking research anddevelopment activities aimed at improving the competitiveness of the business. | Jul 20, 2020 | ||
| Neurovalens delivers innovative solutions in the field of neuroscience, bioscience and neurophysiology.Neurovalens has received support from Invest NI under the European Union’s Investment for Growth and Jobs Programme. The project, recorded on the ERDF beneficiaries’ website, will be implemented over the next one year, undertaking research anddevelopment activities aimed at improving the competitiveness of the business. | $6.5M / Series A / Jul 20, 2020 | ||
| Neurovalens delivers innovative solutions in the field of neuroscience, bioscience and neurophysiology.Neurovalens has received support from Invest NI under the European Union’s Investment for Growth and Jobs Programme. The project, recorded on the ERDF beneficiaries’ website, will be implemented over the next one year, undertaking research anddevelopment activities aimed at improving the competitiveness of the business. | $6.1M / Series A / Mar 14, 2019 | ||
| B-Secur are on a mission to revolutionise the way people experience technology in the connected world using their unique heartbeat. We’ve invested over 15 years of deep, scientific research in ECG to become a world leader in the development and integration of ECG technology, partnering with some of the world's leading technology companies.We’ve harnessed the power of ECG to create HeartKey®, offering advanced physiological monitoring with intrinsic data protection.We have developed a suite of powerful ECG algorithms and analytics for user identification, wellness, and health, ready for integration into leading devices and systems. B-Secur also have a combined 50+ years of in-house hardware and material science, which our partners can use to significantly reduce development costs on hardware and ECG electrode design. B-Secur and HeartKey® bring you our world class expertise in ECG combined with powerful, flexible integration and configuration possibilities to create your optimal product, with a competitive edge. | $5.3M / Series A / Mar 05, 2019 | ||
| MediSieve is a multi-award-winning medical device company developing Magnetic Blood Filtration (MBF), a platform technology for the treatment of blood-borne diseases by physically removing disease relevant targets directly from a patient’s bloodstream. MBF is an extracorporeal technology, similar to dialysis. A patient's blood is continuouslycirculated through an external blood loop containing the MediSieve system. Targeted magnetic particles (TB-MPs) are infused into the loop, binding specifically to disease-relevant targets in the patient's blood. The blood then flows through a magnetic filter which captures the particles and bound targets and the remainder of the blood returns to the patient unaffected; the TB-MPs never enter the patient’s body. MediSieve is based at the Imperial Incubator in White City, London. It has dedicated workshop and laboratory facilities (including capacity for ELISAs, Flow Cytometry and human blood testing) in which products are developed and validated. | $2.3M / Series A / Jun 04, 2018 | ||
| B-Secur are on a mission to revolutionise the way people experience technology in the connected world using their unique heartbeat. We’ve invested over 15 years of deep, scientific research in ECG to become a world leader in the development and integration of ECG technology, partnering with some of the world's leading technology companies.We’ve harnessed the power of ECG to create HeartKey®, offering advanced physiological monitoring with intrinsic data protection.We have developed a suite of powerful ECG algorithms and analytics for user identification, wellness, and health, ready for integration into leading devices and systems. B-Secur also have a combined 50+ years of in-house hardware and material science, which our partners can use to significantly reduce development costs on hardware and ECG electrode design. B-Secur and HeartKey® bring you our world class expertise in ECG combined with powerful, flexible integration and configuration possibilities to create your optimal product, with a competitive edge. | $4.6M / Seed / Jul 25, 2017 | ||
| B-Secur are on a mission to revolutionise the way people experience technology in the connected world using their unique heartbeat. We’ve invested over 15 years of deep, scientific research in ECG to become a world leader in the development and integration of ECG technology, partnering with some of the world's leading technology companies.We’ve harnessed the power of ECG to create HeartKey®, offering advanced physiological monitoring with intrinsic data protection.We have developed a suite of powerful ECG algorithms and analytics for user identification, wellness, and health, ready for integration into leading devices and systems. B-Secur also have a combined 50+ years of in-house hardware and material science, which our partners can use to significantly reduce development costs on hardware and ECG electrode design. B-Secur and HeartKey® bring you our world class expertise in ECG combined with powerful, flexible integration and configuration possibilities to create your optimal product, with a competitive edge. | $3.9M / Seed / Mar 01, 2015 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
SaaS Investors
117,441 investors
Enterprise Investors
92,235 investors
Software Investors
57,331 investors
Health Care Investors
48,627 investors
Biotech Investors
24,131 investors
Biotechnology Investors
21,397 investors
Medical Investors
21,234 investors
SaaS VC Funds
71,923 investors
Enterprise VC Funds
58,939 investors
FAQ
What does Wharton Asset Management Company Limited invest in?
Wharton Asset Management Company Limited invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Venture - Series Unknown stage. Most of the 10 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Wharton Asset Management Company Limited's check size?
Wharton Asset Management Company Limited typically joins rounds of $3.9M–$4.6M at Seed, $1.9M–$6.5M at Series A and $6.7M–$12M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Wharton Asset Management Company Limited participates in.
How do I contact Wharton Asset Management Company Limited?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Wharton Asset Management Company Limited?
The team at Wharton Asset Management Company Limited includes Wharton Asset Management Company Limited (Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
